Medical Frontiers: Examining New Breakthroughs in Cardiovascular Health, Diabetes, and Long COVID

November 21, 2026

The medical landscape is constantly shifting as clinical trials yield data that either validate long-held hypotheses or, more often, challenge the status quo. In this week’s installment of TTHealthWatch, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Dr. Rick Lange, president of Texas Tech Health El Paso, synthesize the most pressing medical research from the past seven days.

This week’s focus—heavily influenced by the latest presentations from the American Heart Association (AHA) and the American College of Rheumatology (ACR)—spans the spectrum of chronic disease management. From the controversial role of lipoprotein(a) in cardiovascular health to the potential for triple-agonist therapies in managing knee osteoarthritis, and the ongoing investigation into metformin’s role in post-acute sequelae of COVID-19, the medical community is finding that the "gold standard" of treatment is often a moving target.


The Cardiovascular Conundrum: Is Lowering Lp(a) the Silver Bullet?

One of the most anticipated discussions centered on the role of lipoprotein(a), or Lp(a), in atherosclerotic cardiovascular disease (ASCVD). Lp(a) has long been recognized as an independent, genetically determined risk factor for cardiovascular events, and for years, clinicians have operated under the assumption that if they could significantly lower these levels, they would inevitably see a reduction in heart attacks and strokes.

Clinical Trial Findings

The study published in the New England Journal of Medicine focused on pelacarsen, an antisense oligonucleotide designed to inhibit the production of Lp(a) in the liver. In a robust trial involving approximately 4,100 participants, researchers administered the drug subcutaneously on a monthly basis. The study spanned 4.7 years, providing a substantial window to observe clinical outcomes.

The medication was undeniably effective in its primary pharmacological goal: lowering Lp(a) levels by 70% to 90%. However, the clinical outcome was a sobering surprise. When researchers tracked major adverse cardiovascular events—specifically death, myocardial infarction, stroke, or the need for coronary revascularization—there was no statistically significant difference between the group treated with pelacarsen and the placebo group. Even among patients with high baseline Lp(a) levels, the expected cardiovascular benefit failed to materialize.

Implications for Future Research

This finding has forced a re-evaluation of how cardiologists perceive Lp(a). Is it a direct driver of atherosclerosis that we simply haven’t learned to manage correctly, or is it a biomarker that correlates with risk without being the primary mechanism of injury? Dr. Lange noted that while reducing standard risk factors like LDL cholesterol remains critical, the "more is better" approach to risk factor reduction does not automatically extend to Lp(a) inhibition. The medical community must now wait for upcoming trials with other agents to see if a different delivery method or mechanism of action yields different results.


Triple-Agonist Therapy: A New Era for Knee Osteoarthritis?

As obesity rates continue to climb globally, the intersection of weight management and orthopedic health has become a focal point for pharmaceutical intervention. The latest research presented at the ACR meeting examined retatrutide, an investigational "triple agonist" that targets the GIP, GLP-1, and glucagon receptors.

Study Methodology

The trial enrolled adults without diabetes who suffered from painful knee osteoarthritis and maintained a BMI of at least 27. Participants were randomized to receive either once-weekly subcutaneous injections of retatrutide or a placebo. The primary endpoints were two-fold: the change in knee pain scores and the percentage change in total body weight at 68 weeks.

Results and the "Chicken or Egg" Debate

The data showed that retatrutide was effective at reducing both weight and pain. However, the trial highlighted a persistent challenge in osteoarthritis research: the placebo effect. While the retatrutide group experienced significant pain reduction, the placebo group also showed a 38% reduction in pain symptoms.

Dr. Lange and Tracey discussed the "chicken or egg" dilemma: does the drug specifically treat joint inflammation, or is the pain reduction simply a downstream effect of weight loss relieving mechanical stress on the knee? While weight loss is known to decrease systemic inflammation by reducing fat cell activity, the significant improvement in the placebo group serves as a reminder of the psychological and physiological complexities of pain management. As with other GLP-1 related therapies, side effects such as nausea and constipation were observed but generally resolved with dose escalation.


Intensive Blood Pressure Lowering in Type 2 Diabetes

The debate regarding how low is "too low" for blood pressure in diabetic patients continues. The latest trial, conducted in Brazil and involving 9,400 ethnically diverse participants, sought to clarify the benefits of intensive blood pressure management.

Comparing Treatment Strategies

Participants were randomized into two groups: one aiming for a systolic blood pressure below 140 mmHg and another aiming for a more aggressive target of below 120 mmHg. Over a four-year follow-up, researchers observed no significant difference in major cardiovascular events between the two groups.

This study adds to a contradictory body of literature. The landmark ACCORD trial previously suggested no benefit to aggressive lowering, while other studies (such as the trial conducted in China) suggested a benefit, particularly regarding stroke reduction. This latest data suggests that in diverse populations, the clinical return on investment for aggressive blood pressure lowering in diabetics—which requires increased polypharmacy and potential for adverse effects like syncope—may be limited.


Metformin and Long COVID: An Emulation Study

Perhaps the most timely topic covered was the use of metformin to prevent the development of long COVID. The study, published in the Journal of Medical Virology, utilized an "emulation" approach to electronic health records to evaluate the impact of metformin administered within six days of a COVID-19 diagnosis.

Understanding Target Trial Emulation

Because randomized controlled trials are not always feasible in rapidly evolving public health crises, researchers used target trial emulation. By comparing "new users" of metformin against users of other non-beneficial medications (such as certain antidepressants or respiratory drugs), researchers accounted for variables like "immortal time bias" and the placebo effect.

Findings and Clinical Outlook

The study found that 4% of the metformin group developed long COVID or died, compared to 8.5% in the control group. These results suggest a potential protective effect of metformin in the acute phase of infection. Dr. Lange expressed a cautious but positive outlook, noting that if a patient presents with a new COVID infection, offering metformin—given its established safety profile—is a reasonable, evidence-backed consideration.


Implications for the Future of Clinical Practice

The common thread linking these four studies is the ongoing refinement of modern medicine. Whether it is the disappointment of a long-hoped-for cardiovascular intervention (Lp(a)), the promise of multi-receptor agonists for weight and joint health (retatrutide), or the creative use of real-world data to find answers for post-viral syndromes (metformin), the message is clear: data-driven, cautious, and patient-centered decision-making remains the gold standard.

Key Takeaways for Practitioners:

  • Cardiovascular Risk: Current Lp(a) inhibitors, while effective at lowering the target molecule, do not yet show clinical improvement in cardiovascular outcomes.
  • Osteoarthritis: Pharmacological weight loss is a powerful tool for knee pain, but the significant placebo response in trials reminds clinicians that pain is multifactorial.
  • Diabetes Care: Aggressive blood pressure targets below 120 mmHg may not provide additional cardiovascular benefit for all diabetic patients and should be weighed against the risks of polypharmacy.
  • Long COVID: Early intervention with metformin at the time of acute COVID-19 infection shows promise in reducing long-term sequelae, warranting discussion between providers and patients.

As medicine progresses, the reliance on "emulation" studies and the rigorous scrutiny of "tried and true" protocols will continue to shape how we treat patients. As Dr. Lange concluded, "Y’all listen up and make healthy choices"—a sentiment that applies as much to the clinical researcher as it does to the patient at home.

More From Author

Champions of Longevity: Announcing the 2026 "Heroes in Health" Honorees